References
- Hitchcock IS, Häfer M, Sangkhae V, Tucker JA The Thrombopoietin receptor: revisiting the master regulator of platelet production. Platelets. 2021;32(6):770–778. doi:https://doi.org/10.1080/09537104.2021.1925102
- Kardeby C, Damaskinaki F-N, Sun Y, Watson SP Is the endogenous ligand for PEAR1 a proteoglycan: clues from the sea. Platelets. 2021;32(6):779–785. doi:https://doi.org/10.1080/09537104.2020.1863938
- Clark JC, Damaskinaki F-N, Cheung YFH, Slater A, Watson SP Structure-function relationship of the platelet glycoprotein VI (GPVI) receptor: does it matter if it is a dimer or monomer? Platelets. 2021;32(6):724–732. doi:https://doi.org/10.1080/09537104.2021.1887469
- Martin EM, Zuidscherwoude M, Morán LA, Di Y, García A, Watson SP The structure of CLEC-2: mechanism of dimerisation and higher order clustering. Platelets. 2021;32(6):733–743. doi:https://doi.org/10.1080/09537104.2021.1906407
- Branfield S, Washington AV The enigmatic nature of the triggering receptor expressed in myeloid cells −1 (TLT- 1). Platelets. 2021;32(6):753–760. doi:https://doi.org/10.1080/09537104.2021.1881948
- Soriano Jerez EM, Gibbins JM, Hughes CE Targeting platelet inhibition receptors for novel therapies: PECAM-1 and G6b-B. Platelets. 2021;32(6):761–769. doi:https://doi.org/10.1080/09537104.2021.1882668
- Harbi M, Smith C, Nicolson P, Watson SP, Thomas M. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. Platelets. 2021;32:29–41. doi:https://doi.org/10.1080/09537104.2020.1849600
- Damaskinaki FN, Moran LA, García A, Kellam B, Watson SP Overcoming challenges in developing small molecule inhibitors for GPVI and CLEC-2. Platelets. 2021;32(6):744–752. doi:https://doi.org/10.1080/09537104.2020.1863939